In the present study, we developed a CD8+ T cell-associated immunological risk prognostic model using CD8+ T cell-associated marker genes obtained from single-cell sequencing analysis to predict the survival status, tumor immune microenvironment, and immunotherapy responsiveness of KIRC patients, thereby providing a potential target and predictive evidence for immunotherapy. The gene discussed is CD8A; the disease is neoplasm.